Yuyu Li

Dr. Yuyu Li


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2025 in iScience
Verified
Journal Article
Open access
JYJiaqi Yu
Jiaqi Yu
YYYa-Nan Yang
Ya-Nan Yang
WCWeiyao Chen
Weiyao Chen
JHJiaxin Hu
Jiaxin Hu
ZJZhechuan Jin
Zhechuan Jin
YLYuyu Li
Yuyu Li
Cardiovascular diseases (CVDs) remain one of the leading causes of death worldwide, imposing a significant societal burden and highlighting the urgent need for effective disease management strategies to reduce mortality and prevent disability. Recently, gut microbiota and its metabolites have been considered as an essential part of human physiology, emphasizing their contributions in CVD development and management. An increasing number of studies have shown that gut microbiota affects the process of CVDs either directly through changes in its composition and function or indirectly through its metabolites, and plays an important role in host physiology and disease development. This review provides a comprehensive overview of how gut microbes and their specific metabolites interact and contribute to the generation and development of CVDs. In addition, the therapeutic potential to treat CVDs by targeting the gut microbiota is also discussed, which may provide promising possibilities for the clinical treatment of CVDs in the future.

15 May 2025 in Journal of Controlled Release
Verified
Journal Article
Open access
YGYanlin Gao
Yanlin Gao
LRLi Rong
Li Rong
JCJing Cui
Jing Cui
WCWei Cheng
Wei Cheng
LFLin Fu
Lin Fu
YLYuyu Li
Yuyu Li
Thoracic aortic dissection (TAD) is a life-threatening cardiovascular disease characterized by rapid progression and high morbidity. Current efforts to develop effective treatment strategies focus on targeting apoptotic aortic endothelial cells and mitigating inflammation. Here, inspired by the inflammation-neutralizing capacity of functional cells, we present multifunctional biomimetic nanovesicles (MM-LPs) co-assembled from macrophage membranes and synthetic lipids for the targeted delivery of Senkyunolide I (SEI) in TAD treatment. The integration of macrophage membranes endows MM-LPs with the ability to selectively target activated vascular endothelial cells (VECs) while adsorbing proinflammatory cytokines to suppress inflammation. Additionally, these nanoparticles enable the controlled release of SEI, leading to significant anti-apoptotic effects. Leveraging these advantages, MM-LPs effectively mitigated VECs activation, reduced apoptosis, and prevented disease progression and rupture in a BAPN (β-aminopropionitrile monofumarate)-induced mouse model of TAD. Furthermore, this system significantly reduced SEI-associated toxicity and adverse effects on the liver and kidneys. These findings highlight the potential of combining natural macrophage membranes with synthetic lipids to develop a multifunctional biomimetic drug delivery system for treating VECs dysfunction while minimizing drug-related side effects.

8 December 2023 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
YTYing Tan
Ying Tan
XBXue Bao
Xue Bao
YLYuyu Li
Yuyu Li
GSGuo Song
Guo Song
HLHe Lu
He Lu
BXBiao Xu
Biao Xu
Purpose: Complete and rapid recanalization of blood flow by percutaneous coronary intervention (PCI) is the most effective intervention for patients with ST-segment elevation myocardial infarction (STEMI). However, myocardial ischemia/reperfusion (I/R) injury leads to microvascular obstruction (MVO), limiting its efficacy. Colchicine can reduce myocardial I/R injury, but its effect on MVO is unclear. Hence, this study aimed to assess the role and mechanism of colchicine on MVO. Methods: Clinical data on STEMI patients with PCI were collected and risk factors related to MVO were analyzed. The rat myocardial I/R model was established to evaluate the MVO by thioflavin S staining. The myocardial I/R model of mice was treated with PBS or colchicine at the reperfusion. The effect of colchicine on cardiomyocyte apoptosis after I/R was evaluated by TUNEL and expression of cleaved caspase-3. ROS levels were detected in H9c2 cells to evaluate the colchicine effect on myocardial oxidative stress. Moreover, the mechanism through which colchicine attenuated MVO was examined using flow cytometry, WB, ELISA, immunohistochemistry, bioinformatics analysis, and immunofluorescence. Results: Multivariate analysis showed that elevated neutrophils were associated with extensive MVO. Colchicine could attenuate MVO and reduce neutrophil recruitment and NETs formation after myocardial I/R. In addition, colchicine inhibited cardiomyocyte apoptosis in vivo and ROS levels in vitro. Furthermore, colchicine inhibited neutrophil proliferation in the bone marrow (BM) by inhibiting the S100A8/A9 inflammatory signaling pathway. Conclusions: Colchicine attenuated MVO after myocardial I/R injury by inhibiting the proliferation of neutrophils in BM through the neutrophil-derived S100A8/A9 inflammatory signaling pathway.

2 April 2026 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
XHXiangyong Hu
Xiangyong Hu
LDLiping Du
Liping Du
HXHongju Xiang
Hongju Xiang
YLYuyu Li
Yuyu Li
ZLZhixiong Liao
Zhixiong Liao
JYJiaqi Yu
Jiaqi Yu
Introduction: Myocardial infarction (MI) triggers an excessive inflammatory response that drives adverse cardiac remodeling. Although colchicine has shown clinical promise, its narrow therapeutic window and lack of target specificity limit its efficacy. To address these limitations, we developed a biohybrid nanovesicle (MM‐LP@COL) that encapsulates colchicine, aiming to leverage natural inflammatory tropism for site-specific drug delivery. Methods: MM‐LP@COL nanovesicles were fabricated by fusing macrophage membranes with liposomes. Physicochemical characterization was performed using DLS, TEM, and FRET analysis. Cytokine‐scavenging capacity was evaluated in vitro by ELISA. In a murine MI model, mice were treated with PBS, free colchicine, LP@COL, or MM‐LP@COL. Immune cell populations in blood, bone marrow, and spleen were analyzed by high‐dimensional flow cytometry (UMAP). Cardiac function and tissue remodeling were assessed by echocardiography and histology. Results: MM‐LP@COL formed uniform spherical nanovesicles (∼200 nm) and demonstrated potent, dose‐dependent neutralization of multiple pro‐inflammatory cytokines in vitro , along with reduced circulating cytokine levels in MI mice. High‐dimensional cytometric analysis revealed that treatment significantly reduced neutrophil infiltration across key immune organs, including blood, bone marrow, and spleen. These effects translated into improved left ventricular function, reduced myocardial inflammation, and attenuated cardiomyocyte hypertrophy. Discussion: This study demonstrates that the macrophage-inspired nanovesicle system constitutes a potent and targeted combinatorial therapy for post-infarction inflammation and repair.